PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.

ABSTRACT:

Purpose

With the broad use of next-generation sequencing assays, it has become clear that mutations in DNA repair genes are more commonly found than previously reported. In advanced prostate cancer patients with BRCA1/2 or ATM mutations, poly (ADP-ribose) polymerase inhibition (PARPi) causes an increased overall survival advantage compared with patients without these mutations. This review explores the advantages and limitations of PARPi treatment and its use beyond BRCA1/2-altered tumors. Furthermore, it discusses the benefits of current biomarkers and what role functional biomarkers and organoids may play in addressing the involvement of homologous recombination repair mutations in tumor development and progression.

Methods

A systematic review was cond

SUBMITTER: von Werdt A 

PROVIDER: S-EPMC8547927 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature